J&J-related uncertainties are behind us now

11/03/25 -"Yesterday, J&J announced it would not exercise its option to license HexaBody-CD38 (previously deemed to be Darzalex’s successor) from Genmab, thereby ending the uncertainty around this ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

11/03/25

Download

You may also be interested by these reports :

17/03/25

Virbac

Virbac’s 2024 operating profitability was somewhat ahead of the street’s expectations, backed by favourable prices, higher volumes and an improved ...

12/03/25

Big Pharma

Roche and Zealand Pharma have agreed to co-develop and co-commercialise Zealand’s phase II weight-loss drug candidate, petrelintide, as monotherapy ...

11/03/25

PolyPeptide

Vague outlook and slight miss on topline might offer weakness to further build up a position

05/03/25

PolyPeptide

Worth building a position ahead of results at current price

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue